LDH Cytotoxicity Assay Kit: Practical Workflow
2026-09-25
The LDH Cytotoxicity Assay Kit measures enzyme activity released into culture medium to support cell cytotoxicity measurement and cell damage quantification. Use it to assess loss of membrane integrity, not to identify a specific cell-death pathway; include appropriate background and release controls, especially when test compounds may interfere with the colorimetric readout.
From Glutathione Loss to Glutamate-Driven Injury
2026-09-25
A translational perspective on what redox biology can—and cannot—tell us about glutaminase research. We connect findings on GSTA1-driven glutathione depletion with the distinct, model-specific use of JHU-083 to investigate glutamate biology in experimental cerebral malaria.
From mRNA Synthesis to In Vivo CAR T Strategy
2026-09-24
In vivo CAR T-cell engineering is shifting the translational question from how to manufacture cells ex vivo to how to deliver a functional genetic instruction in the body. A recent mouse lupus study illustrates the opportunity—and why mRNA design, delivery, and disease-model evidence must be evaluated as distinct parts of one development strategy.
Natural Compounds Against SARS-CoV-2: Docking Evidence
2026-09-24
A 2022 in silico study screened natural compounds against SARS-CoV-2 main protease and the spike receptor-binding domain, identifying several vitamins and related compounds with predicted binding at functionally important sites. The results provide leads for experimental testing, but docking and molecular dynamics do not establish antiviral activity or clinical benefit.
CDCA–FXR–KLF11 Axis in Contrast-Induced AKI
2026-09-23
A 2026 study identifies an FXR–KLF11 transcriptional pathway through which Chenodeoxycholic Acid (CDCA) limits contrast-induced acute kidney injury. Using mouse and HK-2 cell models, the investigators connect direct FXR binding at the KLF11 promoter with suppression of JAK2/STAT3-driven inflammation and apoptosis, providing a mechanistic framework for further preclinical evaluation.
Mechanical Stress, Cytoskeleton, and Autophagy
2026-09-23
The reference study shows that compression-induced autophagy in human cells depends primarily on cytoskeletal microfilaments, while microtubules provide an auxiliary contribution. Its intervention-based design links force transmission to autophagosome responses and offers a useful framework for studying mechanotransduction without equating cytoskeletal remodeling with autophagic flux.
QPRT, PLC Signaling, and Breast Cancer Invasion
2026-09-22
The reference study identifies quinolinate phosphoribosyltransferase (QPRT) as a regulator of breast cancer invasiveness and links its effects to purinergic signaling, Rho–ROCK activity, and myosin light chain phosphorylation. Its combination of genetic manipulation and pathway-directed inhibitors shows how phospholipase C activity can be used to dissect metastatic signaling, while also highlighting the limits of pharmacological pathway assignment.
LLY-507: Interpreting SMYD2 Inhibition
2026-09-21
LLY-507 is a selective SMYD2 inhibitor that connects substrate methylation with cancer and renal-fibrosis biology. This guide focuses on how to interpret orthogonal assays, distinguish catalytic effects from downstream phenotypes, and design more defensible preclinical studies.
NMDA Workflows for Excitotoxicity and Ferroptosis
2026-09-21
NMDA (N-Methyl-D-aspartic acid) enables controlled NMDA receptor activation for excitotoxicity research, calcium influx measurement, and oxidative stress assays. A structured workflow can connect receptor-level injury with ferroptosis markers and the BMP4-GPX4 response described in a recent glaucoma model.
1,2-Dioleoyl-sn-glycero-3-PE (DOPE) Workflow
2026-09-20
1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is a helper phospholipid for cationic liposomes and related lipid nanoparticle formulations used in nucleic acid delivery. This guide covers solvent selection, formulation setup, and QC; it should not be treated as a ready-to-use aqueous reagent, a standalone transfection reagent, or evidence of a defined delivery outcome.
SW033291: From PGE2 Signal to Assay Design
2026-09-19
SW033291 is a potent 15-PGDH inhibitor for connecting prostaglandin E2 elevation with hematopoiesis, tissue regeneration research, and muscle repair. This guide focuses on how to translate target engagement into interpretable cellular, tissue, and functional assays.
EdU Imaging Kits for RCC Proliferation Studies
2026-09-19
EdU Imaging Kits (HF488) convert S-phase DNA synthesis into a quantitative fluorescence readout for microscopy and flow cytometry. Their click-chemistry workflow is particularly useful for testing syringin–sunitinib combinations in renal cell carcinoma while preserving cellular morphology and antigen-binding sites.
Biotin-HPDP and the Redox Logic of Tumor Immunity
2026-09-18
A translational framework for using Biotin-HPDP to connect cysteine-state chemistry, SDHB palmitoylation, tumor metabolism, and T-cell exhaustion in pancreatic cancer research.
AMPK–ULK1 Signaling in Energy Stress
2026-09-18
The reference study challenges the conventional view that AMPK uniformly activates autophagy during glucose deprivation. Its cell-based evidence shows that AMPK can inhibit ULK1 initiation signaling while preserving the autophagy machinery, creating a stress-adaptive model with important implications for interpreting autophagy inhibition experiments.
Foxp1, Notch, and Valvular Calcification in CKD
2026-09-17
This 2026 study identifies endothelial Foxp1 as a protective regulator of chronic kidney disease–associated valvular calcification. Its mechanistic model connects Foxp1 overexpression with repression of Jagged-1/Notch signaling, reduced endothelial-to-mesenchymal transition, preservation of endothelial integrity, and weaker osteogenic activation of valvular interstitial cells.